MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)
Sponsor: AbbVie
A PHASE2 clinical study on Relapsed/Refractory Large B-cell Lymphoma, this trial is actively recruiting participants. The trial is conducted by AbbVie and has accumulated 4 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
May 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Peter MacCallum Cancer Centre, Australia
For direct contact, visit the study record on ClinicalTrials.gov .